Popli S, Daugirdas J T, Neubauer J A, Hockenberry B, Hano J E, Ing T S
Arch Intern Med. 1986 Nov;146(11):2140-4.
In 30 patients with mild essential hypertension, clonidine hydrochloride was delivered from a skin patch reservoir designed to release medication at a constant rate for seven days. After a four-week washout period, patients were randomized (double-blind) into a clonidine- or a placebo-treated group. Clonidine or placebo was then given for five weeks, followed by a two-week washout period to assess withdrawal from treatment. Blood pressure was controlled in 11 of 15 clonidine-treated patients but in only four of 15 placebo-treated patients. The clonidine-treated group evidenced larger decreases in both systolic and diastolic blood pressures. In the clonidine-treated group, blood pressures and plasma clonidine levels were stable throughout a representative seven-day period. Besides mild skin irritation with both clonidine and placebo patches, few side effects were observed. After discontinuation of clonidine administration, plasma levels declined in a non-log linear manner. There was no rebound hypertension. The results suggest that clonidine delivered transdermally is safe and effective for control of mild essential hypertension.
在30例轻度原发性高血压患者中，盐酸可乐定由一个皮肤贴片贮库提供，该贮库设计为以恒定速率释放药物达7天。经过4周的洗脱期后，患者被随机（双盲）分为可乐定治疗组或安慰剂治疗组。然后给予可乐定或安慰剂5周，随后是2周的洗脱期以评估停药情况。15例接受可乐定治疗的患者中有11例血压得到控制，而15例接受安慰剂治疗的患者中只有4例血压得到控制。可乐定治疗组的收缩压和舒张压下降幅度更大。在可乐定治疗组中，在一个代表性的7天期间内血压和血浆可乐定水平保持稳定。除了可乐定和安慰剂贴片均引起轻度皮肤刺激外，几乎未观察到副作用。停用可乐定给药后，血浆水平呈非对数线性下降。未出现反跳性高血压。结果表明，经皮给予可乐定对于控制轻度原发性高血压是安全有效的。
